Pleasanton, CA, April 3, 2014 For the second consecutive year, CooperVision is proud to offer the CooperVision Science and Technology Awards Program. The goal of this awards program is to bring recipients and CooperVision scientists together to explore new areas of technology advancement in contact lens applications. CooperVision recognizes and highly values the discovery of innovative ideas that have the potential to deliver benefits to current and future contact lens wearers around the world.
“CooperVision is fully committed to fostering translational research from external sources, and this awards program is the ideal platform to act on that commitment,” said Arthur Back, Chief Technology Officer for CooperVision. “The fiscal year 2014 program was a great success with multiple awards funded. These awards allow scientists to bring their ideas forward as well as provide the means to translate the award recipients’ theories into practical opportunities that expand the applications with contact lenses.”
The CooperVision S&T Awards Program is comprised of two awards: The CooperVision Seedling Award and the CooperVision Translational Research Award. Research proposals should demonstrate significant potential for research discoveries and technological advancements that CooperVision can rapidly commercialize to improve the performance, enhance the functionality, and/or broaden the use of contact lenses.
The CooperVision Seedling Award is intended to incentivize collaborations with CooperVision in a new research area for a one-year period. The award enables investigators to generate preliminary data that could be used toward a future CooperVision Translational Research Award. The maximum total cash amount for a CooperVision seedling is $100,000, including indirect costs.
A CooperVision Translational Research Award is a multi-year award for a substantive translational research project. Research under this award is milestone-driven in order to remain focused on a well-defined goal. A CooperVision Translational Research Award provides funding for up to two years, totaling up to $400,000, including indirect costs. A maximum of $250,000 can be requested for any one year. A CooperVision Translational Research Award may be considered for renewal at the end of the initial research period.
For information of the application process and materials, please visit http://coopervision.com/our-company/science-and-technology-awards.
# # #
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market-leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, Calif., Cooper has approximately 8,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.